Abstract
A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Current HIV Research
Title: Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs
Volume: 9 Issue: 8
Author(s): Olaf Kutsch, Frank Wolschendorf and Vicente Planelles
Affiliation:
Keywords: HIV-1 latency, drug screening, cytokine storm, LTR, chromatin structures, J-LAT, FK506, GFP-positive cells, screening effort
Abstract: A curative therapy for HIV-1 infection will have to include measures to eliminate the reservoir of latently HIV- 1 infected cells that allow the virus to persist despite otherwise successful therapy. To date, all efforts to deplete the latent reservoir by triggering viral reactivation have used preexisting drugs that are believed to potentially target molecular mechanisms controlling HIV-1 infection. These therapeutic attempts were not clinically successful. Only in the last few years have cellular models of latent HIV-1 infection suitable for high throughput screening been developed and concerted drug discovery efforts were initiated to discover new HIV-1 reactivating drugs. We here provide a historic overview about the development of cell models with latent HIV-1 infection that lend themselves to drug discovery. We provide an overview from the first reported latently infected cell lines to current in vitro models of latent HIV-1 infection in primary T cells, and compare their potential to be used in future large-scale drug screening efforts.
Export Options
About this article
Cite this article as:
Kutsch Olaf, Wolschendorf Frank and Planelles Vicente, Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998826
DOI https://dx.doi.org/10.2174/157016211798998826 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Molecular Cytogenetics of Autism
Current Genomics Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Characterisation of a Neural Teratogenicity Assay Based on Human ESCs Differentiation Following Exposure to Valproic Acid
Current Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy Bioactivity Guided Isolation of Quercetin as Anxiolytic Compound from Elaeocarpus ganitrus Beads
The Natural Products Journal Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats
Current Alzheimer Research Structural MRI Biomarkers of Mild Cognitive Impairment from Young Elders to Centenarians
Current Alzheimer Research Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research 5-HT7 Receptor Ligands: Recent Developments and Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery The New Patient and Responsible Self-Medication Practices: A Critical Review
Current Drug Safety